Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10959845 | 0.83 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL951298 | 0.83 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| Butane SCHEMBL11313859 | 0.83 | LMNA (0.44) | LMNACA12CA1CA2CA3 | |
| SCHEMBL7062342 | 0.81 | LMNA (0.40) | LMNACA12CA1CA2CA3 | |
| SCHEMBL11313871 | 0.80 | LMNA (0.44) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3728882 | 0.78 | LMNA (0.46) | LMNACA12CA1CA2CA3 | |
| SCHEMBL7514608 | 0.78 | PIM1 (0.38) | LMNACA12CA1CA2CA3 | |
| Cadaverine Tartrate SCHEMBL28780458 | 0.77 | LMNA (0.37) | LMNACA12CA1CA2CA3 | |
| SCHEMBL11187859 | 0.77 | LMNA (0.45) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28109752 | 0.77 | LMNA (0.45) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077709-A1 | Neuronal death inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | claimed |
| US-6417220-B2 | A MEDICINE FOR PREVENTIVE/TREATMENT OF DISEASE CAUSED BY MITOCHONDRIAL MEMBRANE DEPOLARIZATION BECAUSE OF ELEVATION OF INTRACELLULAR CALCIUM ION CONCENTRATION; BENZODIAZEPINE RECEPTOR ANTAGONIST, E.G.,NEFIRACETAM; ANTIISCHEMIC AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-07-09 | — | — | US | claimed |
| EP-1180366-A9 | NEURONAL DEATH INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-04-24 | — | — | EP | claimed |
| EP-1180366-A1 | NEURONAL DEATH INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-20 | — | — | EP | claimed |
| US-20010051641-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2001-12-13 | — | — | US | claimed |
| EP-1022029-A1 | NOOTROPIC AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-26 | — | — | EP | claimed |
| EP-0953356-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-11-03 | — | — | EP | claimed |
| US-6417220-B2 | A MEDICINE FOR PREVENTIVE/TREATMENT OF DISEASE CAUSED BY MITOCHONDRIAL MEMBRANE DEPOLARIZATION BECAUSE OF ELEVATION OF INTRACELLULAR CALCIUM ION CONCENTRATION; BENZODIAZEPINE RECEPTOR ANTAGONIST, E.G.,NEFIRACETAM; ANTIISCHEMIC AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| EP-1180366-A9 | NEURONAL DEATH INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-04-24 | — | — | EP | disclosed |
| EP-1180366-A1 | NEURONAL DEATH INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
| US-20010051641-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-1022029-A1 | NOOTROPIC AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-26 | — | — | EP | disclosed |
| EP-0953356-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077709-A1 | Neuronal death inhibitors | CASP3, CASP1, AIFM1 | LMNA 1030/4885CA12 3803/4885CA1 132/4885 |
| US-20010051641-A1 | MITOCHONDRIAL MEMBRANE STABILIZER | TFAM, MDH2, NLN | LMNA 743/4885CA12 3968/4885CA1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.